- Revenue growth in 2022 of +12% to €51.6 million and EBITDA
margin of 12%
- Strong cash position of €11.5 million as at December 31,
2022
- Confirmation of the Group's financial objectives for
2024
Regulatory News:
Groupe Berkem (Paris:ALKEM), a leading player in bio-based
chemistry (ISIN code: FR00140069V2 - ticker: ALKEM), announces
its consolidated results for the year ended December 31, 2022, as
approved by its Board of Directors on May 16, 2023. The audit
procedures on the annual accounts have been conducted and the
auditors' report is being issued. Groupe Berkem also provided an
update on its recent business trends and outlook.
Olivier Fahy, Chairman and Chief Executive Officer of Groupe
Berkem stated: “The geopolitical context combined with the
general increase in our operating expenses due to the inflation we
are experiencing weighed heavily on our margins during the fiscal
year 2022. Despite these adverse conditions, we continued to
structure the Group to best support its growth dynamic. As proof of
the resilience of our model, Groupe Berkem managed to recover its
pre-crisis level of normative margin. In 2023, we intend to further
streamline our cost structure through the synergies offered by our
recent acquisitions. Also, with a preserved cash position, we keep
all the necessary latitude to carry out new external operations and
confirm our financial objectives for 2024.”
2022 FULL-YEAR RESULTS
2022 income statement
In thousands of euros – IFRS standards
31/12/2022
31/12/2021
Revenue
51,566
46,049
Cost of goods and services sold
(35,613)
(28,645)
Gross profit
15,953
17,404
Research & Development
(1,731)
(387)
Sales and Marketing
(7,483)
(6,266)
General and administrative expenses
(5,585)
(4,235)
Recurring operating income
1,154
6,516
Other operating income
713
418
Other operating expenses
(2,395)
(1,347)
Operating income
(527)
5,587
Financial income
147
225
Financial expenses
(1,018)
(3,719)
Financial income
(871)
(3,494)
Corporate tax
(169)
(899)
Net income
(1,567)
1,193
Growth of +12% in revenue and EBITDA margin of 12% in
2022
As of December 31, 2022, Groupe Berkem's Full-Year revenue
reached €51.8 million, up 12.4% compared to the 2021 financial
year. Over the year, the Plant Extraction division contributed
30.9% of revenue to December 31, 2022, or €15.9 million. The
revenue of the Formulation division amounted to €35.8 million,
representing 69.1% of the Group's total revenues in 2022. This
revenue from the formulation division rose sharply in 2022, thanks
in particular to the acceleration of demand for bio-based solutions
in the construction sector, but also in the pest control
market.
In 2022, the costs of products and services sold amounted to
€35.6 million, up +24% compared with 2021. This increase is due to
the rise in the price of raw materials, direct labor, and energy,
all of which are due to the geopolitical context. As a result,
the Group's gross profit was €15.9 million in 2022.
Groupe Berkem made significant investments in R&D and
regulatory affairs to strengthen its "product" innovations and
secure marketing authorizations. €1.7 million was invested in 2022,
which is 4.5 times the amount invested in 2021.
At the same time, Groupe Berkem increased its marketing and
sales expenses to promote the Group's products and activities to
target audiences and has also strengthened its teams with a number
of recruitments to support the Group's growth.
As a result, in 2022, recurring operating income amounted to
€1.1 million, compared with €6.5 million in 2021, and operating
income to €0.5 million.
The Group's EBITDA1 reached €6.19 million compared to
€9.4 million in 2021 and the EBITDA margin was 12%.
In 2022, financial income and expenses amounted to -€0.87
million and corporate income tax to -€0.17 million. As a result,
the Group's share of net income will be -€1.57 million in
2022, compared with €1.20 million in 2021.
Cash position as at December 31, 2022
On July 26, 2022, the Group strengthened its financial structure
by setting up a €70 million financing, including €63.5 million in
senior debt with a pool of 6 French banks and €6.5 million in
Recovery Bonds2. These financial resources provide the Group with
greater resources to carry out external growth operations. As of
December 31, 2022, only €21 million of the €70 million had been
drawn down.
As of December 31, 2022, Groupe Berkem held a strong cash
position of €11.5 million.
2022 AND POST-CLOSING HIGHLIGHTS
M&A operations
In February 2023, Groupe Berkem announced the completion of the
acquisition of i.Bioceuticals, Inc. from the Dutch company INC
(International Nutrition Company), the leading North American
distributor of nutritional ingredients. The acquisition of this
subsidiary enables the Group to distribute directly in North
America its complete range of antioxidant active ingredients and to
broaden its offer by addressing the Nutraceutical segment.
Also, in early April 2023, the Group announced the strategic
acquisition of Biopress, a French producer of 100% vegetable oils
and proteins. With this transaction, the Group now benefits from a
local supply of technical vegetable oils, consolidates its offer
for the "Health, Beauty & Nutrition" business segment and
secures new commercial opportunities in the food market.
Activity
In March 2022, Groupe Berkem launched its range of 100%
bio-based resins for the building paint market. This range has been
developed from raw materials of bio-based and renewable origin,
which can be substituted for raw materials of petrochemical
origin.
In June 2022, Groupe Berkem and the SOPREMA Group signed a
collaboration agreement to market an insulating panel incorporating
a bio-based antifungal solution developed by Groupe Berkem.
International and Regulatory Affairs
In October 2022, Groupe Berkem announced an exclusive
partnership in North America with the company Barentz, for the
distribution of the Group's sustainable ingredients in the "Health,
Beauty & Nutrition" market. This exclusive collaboration was
extended in November 2022, with Barentz also becoming the exclusive
distributor of Groupe Berkem's sustainable ingredients in Germany,
Austria and German-speaking Switzerland.
In March 2023, the Group announced the extension of the
distribution agreement with Unipex, already a distributor of the
Group's plant extracts in France, to the territories of Benelux and
French-speaking Switzerland for all its ingredients dedicated to
the cosmetics and personal care market.
In April 2023, Groupe Berkem continued to strengthen its
international expansion strategy by signing a partnership with
Kreglinger for the distribution of its cosmetic ingredients in the
United Kingdom.
At December 31, 2022, the Group held 189 marketing approvals and
a further 73 applications were currently under review.
2023 First-Quarter Revenue
On April 27, 2023, Groupe Berkem reported its revenue for the
first quarter of 2023 and presented the new breakdown of its
revenue between its four business segments:
- Construction & Materials;
- Hygiene & Protection;
- Health, Beauty & Nutrition and
- Industry.
As at March 31, 2023, Groupe Berkem's revenue for the first
three months of 2023 reached €14.5 million, compared with €13.8
million in the first quarter of 2022, reflecting an increase of
5.1%.
OUTLOOK
Confirmation of financial targets for 2024
The Group confirms its ambition to achieve revenue of at least
€85 million by 2024, following the external growth transactions
carried out. By the same date, the Group's objective is to achieve
an EBITDA margin of around 25%.
Publication of the 2022 annual report
The 2022 annual report is available on the Company’s website and
was filed with the AMF this day.
Next financial reports:
- Annual General Meeting: June 22, 2023 (as opposed to the date
announced on April 27, 2023)
- 2023 First-Half Revenue: July 31, 2023 (after market
close)
ABOUT GROUPE BERKEM
Founded in 1993 by Olivier Fahy, Chairman and Chief Executive
Officer, Groupe Berkem is a leading force in the bio-based
chemicals market. Its mission is to advance the environmental
transition of companies producing the chemicals used in everyday
life (Construction & Materials, Health, Beauty & Nutrition,
Hygiene & Protection, and Industry). By harnessing its
expertise in both plant extraction and innovative formulations,
Groupe Berkem has developed bio-based boosters—unique high-quality
bio-based solutions augmenting the performance of synthetic
molecules. Groupe Berkem achieved revenue of €51.6 million in 2022.
The Group has almost 200 employees working at its head office
(Blanquefort, Gironde) and 3 production facilities in Gardonne
(Dordogne), La Teste-de-Buch (Gironde), and Chartres
(Eure-et-Loir).
Groupe Berkem has been listed on Euronext Growth Paris since
December 2021 (ISIN code: FR00140069V2 - ALKEM).
www.groupeberkem.com
_________________________________ 1 Earnings Before Interest,
Taxes, Depreciation and Amortization (EBITDA), corresponds to the
operating resources generated by the Group taking into account
other operating income and other operating expenses, but excluding
depreciation and amortization and the Group's financing policy. 2
See press release issued on 26 July 2022.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230516005900/en/
Groupe Berkem Olivier Fahy,
Chairman and CEO Anthony Labrugnas, Chief Financial Officer Phone:
+33 (0)5 64 31 06 60 investisseurs@berkem.com
NewCap Investor Relations
Mathilde Bohin / Nicolas Fossiez Phone: +33 (0)1 44 71 94 94
berkem@newcap.eu
NewCap Media Relations
Nicolas Merigeau / Antoine Pacquier Phone: +33 (0)1 44 71 94 94
berkem@newcap.eu
Grafico Azioni Groupe Berkem (EU:ALKEM)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Groupe Berkem (EU:ALKEM)
Storico
Da Mag 2023 a Mag 2024